VL-102

VL-102 is a novel, brain-bioavailable small molecule stimulator of soluble guanylyl cyclase (sGC), the primary high-affinity receptor for nitric oxide (NO) in the body. Developed by researchers at the University of Illinois, it was used preclinically to investigate the role of sGC in migraine pathophysiology, where it induced dose-dependent acute and chronic mechanical cephalic and hind-paw allodynia in mice, mimicking migraine-like hyperalgesia, and increased c-fos and CGRP expression in the trigeminovascular complex. This hyperalgesia was blocked by acute (sumatriptan) and preventive (propranolol, topiramate) migraine medications, suggesting sGC super-activation contributes to migraine chronicity and highlighting potential for sGC inhibitors as novel therapies, though VL-102 itself remains a research tool with pending R&D status.[1][4][10][13]